ArticleJournal of translational medicine2026
Heterogeneous-structural bilamellar bionic scaffold for integrated regeneration of tarso-conjunctival composite tissue.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDefects in the posterior lamella of the eyelid are prevalent in the clinical settings, which comprises the tarsal plate and conjunctiva and has limited regenerative capacity. Currently, homogenous scaffolds are used for repair, but they fail to recapitulate the natural bilayer structure and reepithelialization. In this study, we designed a bilamellar scaffold (bGA-ADM) with a heterogeneous structure to repair such defects and promote the integrated regeneration of tarso-conjunctival composite tissue.
methodsbGA-ADM was prepared by homogenization, freezing, freeze-drying, heat-vacuum crosslinking, and glutaraldehyde crosslinking, and its physiochemical properties were subsequently characterized. Fibroblasts, endothelial cells, and meibomian gland epithelial cells were seeded in the dermal layer, whereas mucosal epithelial cells were seeded onto the basement membrane layer to validate cytocompatibility and structural heterogeneity. Rabbit ear and eyelid implantation models were used to confirm in vivo biocompatibility and vascularization of bGA-ADM, and an eyelid posterior lamellar defect model was employed to evaluate its repairing efficacy. RNA sequencing was further performed to investigate the potential of bGA-ADM for meibomian gland construction.
resultsbGA-ADM exhibited biomimetic mechanical properties that provided adequate structural support, and allowed adaptive deformation. Consisting of a patterned basement membrane layer and a spongy dermal layer, it supported the stratified growth of fibroblasts, endothelial cells, meibomian gland epithelial cells, and mucosal epithelial cells in vitro. It also enhanced cellular infiltration and vascularization, thereby accelerating tissue regeneration in both ear and eyelid implantation models. When applied to repair the posterior lamellar defects in situ, bGA-ADM adaptively regenerated tissue closely resembling the native tissues, characterized by matrix deposition and conjunctival resurfacing. Furthermore, it fostered a microenvironment that suppressed inflammation in meibomian gland epithelial cells, contributing to subsequent regeneration of the meibomian gland.
conclusionbGA-ADM presents a promising candidate for the repair of posterior lamellar eyelid defects, and holds substantial potential for clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.